VALBIOTIS is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, VALBIOTIS offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-12 Earnings release - Q2 2026

More about the company

07-22	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT

Market Cap	19.26M 0 22.24M 18M 16.45M 31M 2.12B 31.48M 211M 82.82M 1.06B 83.53M 81.7M 3.53B	P/E 2026 *	-3.54x	P/E 2027 *	-10.2x
Enterprise Value	25.16M 0 29.06M 23.51M 21.49M 40.5M 2.77B 41.13M 276M 108M 1.39B 109M 107M 4.62B	EV / Sales 2026 *	8.12x	EV / Sales 2027 *	2.36x
Free-Float	97.31%	Yield 2026 *	-	Yield 2027 *	-

07-22	Valbiotis Publishes Results of Reverse-It Clinical Study Evaluating Totum 63 in Nature Communications	CI
06-29	Valbiotis Raises EUR10 Million for Commercial Development, Working Capital	MT
06-26	Valbiotis successfully completes a €10.2m capital increase
06-08	Valbiotis Secures Exclusive Distributor in Qatar	MT
06-08	Valbiotis and Al Danah Medical Company Signs Exclusive Distribution Agreement for Valbiotispro Range in Qatar	CI
06-08	Valbiotis strengthens Middle East presence through Qatar partnership
05-27	Valbiotis SA Announces EU Member States Vote in Favor of Regulation Banning Monacolins From Red Yeast Rice	CI
05-12	Valbiotis shares surge on Asian expansion plans
05-12	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris
05-11	Valbiotis and Aika Form Joint Venture and Establish Subsidiary in Singapore	CI
05-11	Pluxee, Lacroix, Valbiotis... stocks to watch tomorrow in Paris
05-11	Valbiotis continues Asian expansion with the establishment of a Singapore subsidiary
05-11	Valbiotis announces creation by Chinese JV of subsidiary in Singapore	RE

05-12	Valbiotis shares surge on Asian expansion plans
30/10/24	Valbiotis: Invest Securities reduces its target
17/07/23	Valbiotis: Invest Securities confirms its recommendation
25/05/23	Valbiotis: Oddo BHF raises its target price
23/05/23	Valbiotis: promising study, Invest Sec. raises its target

07-27	VALBIOTIS SA: Cardiovascular Prevention Act: A response to a major public health challenge A milestone fully aligned with Valbiotis’ mission	EQ
07-22	VALBIOTIS SA: Results of the REVERSE-IT clinical study published in Nature Communications, a major international scientific recognition for the ingredient Totum•63	EQ
06-26	VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M	EQ
06-08	VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained PSR in the amount of €10.2M secured by commitments amounting to 76.6%	EQ
06-08	VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East	EQ

VALBIOTIS Stock Euronext Paris

Stocks

FR0013254851

Biotechnology & Medical Research

Valuation: VALBIOTIS

Latest news : VALBIOTIS

Analysts' recommendations: VALBIOTIS

Press Releases: VALBIOTIS

News in other languages: VALBIOTIS

Managers and Directors: VALBIOTIS

Bio Therapeutic Drugs

Financials

Company Profile

07-27	VALBIOTIS SA: Loi sur la prévention cardiovasculaire : Une réponse à un enjeu de santé public majeur Une avancée en pleine cohérence avec la mission de Valbiotis
07-22	VALBIOTIS SA: Les résultats de l’étude clinique REVERSE-IT publiés dans Nature Communications, une reconnaissance scientifique internationale majeure pour l’ingrédient Totum•63
07-22	VALBIOTIS SA: Bilan semestriel du contrat de liquidité.
06-29	Bourse : Ipsen rachète Kartos, Google et Meta se chicanent, Samsung et SK investissent
06-29	Le marché prend une partie de ses bénéfices sur l'IA

Manager	Title	Age	Since
Sebastien Peltier CEO	Chief Executive Officer	-	-
Stanislas Sordet DFI	Director of Finance/CFO	-	01/03/2024
Pascal Sirvent CTO	Chief Tech/Sci/R&D Officer	-	01/09/2017

Director	Title	Age	Since
Laurent Lévy CHM	Chairman	55	01/03/2017
Jean Zetlaoui BRD	Director/Board Member	-	26/10/2017
Agnès Tixier BRD	Director/Board Member	-	18/03/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.21%	+25.56%	+77.96%	+104.49%	70.85B
ARGENX SE	-1.85%	+3.41%	+36.08%	+65.56%	55.41B
INSMED INCORPORATED	-1.89%	+34.36%	+17.53%	+491.55%	29.43B
WUXI BIOLOGICS (CAYMAN) INC.	-0.30%	+13.64%	+54.71%	+6.07%	24.12B
BIONTECH SE	-0.06%	+1.18%	-15.40%	-13.55%	23.31B
GENMAB A/S	-0.28%	+6.23%	+46.96%	-21.73%	18.37B
PHARMAESSENTIA CORPORATION	+7.26%	+14.16%	+221.03%	+393.89%	16.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	0.00%	+9.69%	+31.01%	+584.59%	16.1B
EXELIXIS, INC.	+0.04%	-4.52%	+42.93%	+148.47%	13.12B
Average	+0.82%	+391.33%	+56.98%	+195.48%	29.75B
Weighted average by Cap.	+0.95%	+350.63%	+54.84%	+160.57%

	2026 *	2027 *
Net sales	3.1M 0 3.58M 2.9M 2.65M 4.99M 342M 5.07M 33.98M 13.33M 171M 13.45M 13.15M 569M	12.8M 0 14.79M 11.96M 10.93M 20.61M 1.41B 20.93M 140M 55.05M 705M 55.52M 54.31M 2.35B
Net income	-8.2M -0 -9.47M -7.66M -7M -13.2M -903M -13.41M -89.88M -35.27M -452M -35.57M -34.79M -1.51B	-2.8M -0 -3.23M -2.62M -2.39M -4.51M -308M -4.58M -30.69M -12.04M -154M -12.14M -11.88M -514M
Net Debt	5.9M 0 6.82M 5.51M 5.04M 9.5M 650M 9.65M 64.67M 25.38M 325M 25.59M 25.03M 1.08B	10.9M 0 12.59M 10.19M 9.31M 17.55M 1.2B 17.82M 119M 46.88M 601M 47.28M 46.25M 2B

End-of-day quote Euronext Paris Other stock markets
- ^PTS	-